MafA Antibody - #DF13429

(1)   (2)  
Product: MafA Antibody
Catalog: DF13429
Description: Rabbit polyclonal antibody to MafA
Application: WB
Reactivity: Human, Mouse, Rat
Prediction: Bovine, Dog, Chicken
Mol.Wt.: 36kDa; 37kD(Calculated).
Uniprot: Q8NHW3
RRID: AB_2846448

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Bovine(88%), Dog(88%), Chicken(100%)
Clonality:
Polyclonal
Specificity:
MafA Antibody detects endogenous levels of total MafA.
RRID:
AB_2846448
Cite Format: Affinity Biosciences Cat# DF13429, RRID:AB_2846448.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

HMafA; Mafa; MAFA_HUMAN; Pancreatic beta cell specific transcriptional activator; Pancreatic beta-cell-specific transcriptional activator; RIPE3b1; Transcription factor MafA; Transcription factor RIPE3b1; v maf musculoaponeurotic fibrosarcoma oncogene homolog A (avian); v maf musculoaponeurotic fibrosarcoma oncogene homolog A; V-maf musculoaponeurotic fibrosarcoma oncogene homolog A;

Immunogens

Immunogen:
Uniprot:

Q8NHW3(MAFA_HUMAN) >>Visit HPA database.

Gene(ID):
MAFA(389692)
Expression:
Q8NHW3 MAFA_HUMAN:

Expressed in the islets of Langerhans (at protein level).

Sequence:
MAAELAMGAELPSSPLAIEYVNDFDLMKFEVKKEPPEAERFCHRLPPGSLSSTPLSTPCSSVPSSPSFCAPSPGTGGGGGAGGGGGSSQAGGAPGPPSGGPGAVGGTSGKPALEDLYWMSGYQHHLNPEALNLTPEDAVEALIGSGHHGAHHGAHHPAAAAAYEAFRGPGFAGGGGADDMGAGHHHGAHHAAHHHHAAHHHHHHHHHHGGAGHGGGAGHHVRLEERFSDDQLVSMSVRELNRQLRGFSKEEVIRLKQKRRTLKNRGYAQSCRFKRVQQRHILESEKCQLQSQVEQLKLEVGRLAKERDLYKEKYEKLAGRGGPGSAGGAGFPREPSPPQAGPGGAKGTADFFL

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Chicken
100
Bovine
88
Dog
88
Pig
0
Horse
0
Sheep
0
Xenopus
0
Zebrafish
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q8NHW3 As Substrate

Site PTM Type Enzyme
S14 Phosphorylation P28482 (MAPK1) , Q13233 (MAP3K1) , Q16539 (MAPK14)
K32 Sumoylation
S49 Phosphorylation P49840 (GSK3A) , P49841 (GSK3B)
T53 Phosphorylation P49841 (GSK3B) , P49840 (GSK3A)
T57 Phosphorylation P49840 (GSK3A) , Q16539 (MAPK14) , P49841 (GSK3B) , O15264 (MAPK13)
S61 Phosphorylation P49841 (GSK3B) , P49840 (GSK3A)
S65 Phosphorylation P28482 (MAPK1) , Q13233 (MAP3K1)
T134 Phosphorylation O15264 (MAPK13) , Q16539 (MAPK14)
Y314 Phosphorylation
S336 Phosphorylation O15264 (MAPK13)

Research Backgrounds

Function:

Transcription factor that activates insulin gene expression. Acts synergistically with NEUROD1/BETA2 and PDX1. Binds the insulin enhancer C1/RIPE3b element. Binds to consensus TRE-type MARE 5'-TGCTGACTCAGCA-3' DNA sequence.

PTMs:

Ubiquitinated, leading to its degradation by the proteasome.

Phosphorylated at tyrosines.

Subcellular Location:

Nucleus.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in the islets of Langerhans (at protein level).

Subunit Structure:

Forms homodimers or heterodimers. Monomers and dimers are able to bind DNA, but the off-rate is faster for monomers. Interacts with NEUROD1 and PDX1 (By similarity). May interact with MAFB, FOS, JUN and PCAF (By similarity).

Family&Domains:

Belongs to the bZIP family. Maf subfamily.

Research Fields

· Human Diseases > Endocrine and metabolic diseases > Type II diabetes mellitus.

· Human Diseases > Endocrine and metabolic diseases > Maturity onset diabetes of the young.

References

1). Inhibition of miR-146a-5p and miR-8114 in Insulin-Secreting Cells Contributes to the Protection of Melatonin against Stearic Acid-Induced Cellular Senescence by Targeting Mafa. Endocrinology and Metabolism (PubMed: 36475359) [IF=3.4]

Application: WB    Species: Mouse    Sample: β-TC6 cells

Fig. 6. V-maf musculoaponeurotic fibrosarcoma oncogene homolog A (Mafa) is a direct target of miR-146a-5p and miR-8114. (A) Effect of melatonin on Mafa protein levels in stearic acid (SA)-treated β-TC6 cells. (B, C) Predicted binding sites between miR-146a/miR-8114 and Mafa, respectively. (D, E) Changes in levels of Mafa mRNA and Mafa protein after transfection of anti-miRNA oligonucleotides (AMO)- 146a-5p in SA-treated β-TC6 cells, respectively. (F, G) Mafa mRNA and Mafa protein levels after inhibition of miR-8114 in the presence of SA, respectively. (H, I) Overexpression of miR-146a-5p decreased Mafa mRNA and Mafa protein levels in the absence of SA, respectively. (J, K) Transfection of miR-8114 mimic alone inhibited the expression of Mafa mRNA and Mafa protein, respectively. (L) Luciferase activity between Mafa and miR-146a-5p or miR-8114, respectively. Each experiment was repeated independently three (A-K) or four (L) times. UTR, untranslated region; WT, wild-type; MUT, mutant; NS, no significance. aP

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.